Micro-vascular and renal complications in diabetic patients are a considerable clinical challenge. In a previous study, we found a significant decrease in vascular endothelial growth factor A (VEGF-A) mRNA levels in glomeruli from patients with diabetic nephropathy (DN). We now set out to investigate the relationship between reduced VEGF-A and connective tissue growth factor (CTGF) expression levels, the number of podocytes, and the extent of interstitial fibrosis. Laser capture microdissection was applied to obtain glomerular RNA from 28 patients with DN and 22 controls. mRNA levels of VEGF-A, CTGF, nephrin, podocin, and Wilms tumor1 (WT1) were measured using real-time polymerase chain reaction. Protein expression was evaluated using immuno-stainings for VEGF-A and CTGF, as well as markers for podocytes (WT1) and endothelial cells (CD31). We found a significant decrease in glomerular mRNA levels for VEGF-A (2.5 times), CTGF (1.6), nephrin (2.8), podocin (3.3) , and WT1 (1.7) in patients with DN. There was a significant correlation between expression of podocyte markers and VEGF-A mRNA levels, and an inverse correlation between podocin message and the extent of interstitial fibrosis. CD31-positive area was significantly decreased (3.2 times) in patients with DN. Reduction of angiogenic factors correlated with the extent of interstitial fibrosis. This downregulation was related to a reduction of podocytes in DN. The results may suggest that downregulation of VEGF-A and CTGF in DN is a result of podocyte loss.
Diabetic nephropathy (DN) is a major complication of both type I and type II diabetes. It is the most common single cause of end-stage renal disease. 1, 2 One of the earliest clinical signs of DN is microalbuminuria, which may progress to proteinuria 3 and hyperfiltration followed by a decrease in the glomerular filtration rate.
Morphologically, DN is characterized by glomerular hypertrophy, expansion of the mesangial matrix, and thickening of glomerular and tubular basement membranes. 4, 5 In later stages of the disease, glomerulosclerosis and interstitial fibrosis are prominent.
Although many factors, including high glucose, insulin, advanced glycation end products , and high blood pressure have been found to play a role in the initiation and progression of DN, the precise molecular mechanisms are still unclear. Several cytokines and growth factors have been proposed to mediate the development of DN. Transforming growth factor-b1 is the most widely investigated molecule in relation to diabetic glomerulosclerosis and interstitial fibrosis, most notably in animal models. 6 Vascular endothelial cell dysfunction is a common finding in patients with type II diabetes mellitus. 7 This may be related to dysregulation of angiogenic factors, such as vascular endothelial growth factor(VEGF-A). In diabetic retinopathy, a condition that may lead to loss of vision, neovascularization has been linked to increased expression of VEGF-A in nonvascular cells of the retina. 8 A role for VEGF-A in DN has also been described. In streptozotocin (STZ)-induced diabetic rats, treatment with monoclonal anti-VEGF antibodies decreased hyperfiltration, albuminuria, and glomerular hypertrophy. 9 In contrast, another study reported that VEGF is reduced in rat glomeruli 1 week after diabetes induction with STZ. 10 Studies in mice carrying one hypomorphic VEGF-A allele and one podocyte-specific null VEGF-A allele have shown that VEGF-A production by the podocyte is critical for endothelial cell migration, survival, proliferation, and differentiation within the glomerulus. 11 In human DN, it has been suggested that VEGF-A is important for maintaining glomerular endothelial cell function and that a decrease in local VEGF-A levels accounts for abnormal remodelling of the glomerular capillaries. 12, 13 Thus, endothelial cell loss may be involved in the development of renal disease and the progression to sclerosis. Apart from VEGF-A, several other growth factors play a role in angiogenesis. For example, connective tissue growth factor (CTGF) has been shown to regulate invasive new vessel formation. 14, 15 Reduction of VEGF-A and CTGF may be a result of podocyte loss, a phenomenon that has been described in DN. 16, 17 Despite recent progress in elucidating the role of perturbed vascular biology in progressive renal disease, the role of VEGF-A and CTGF in the pathogenesis of DN is still unclear. 18 In a previous study, using gene expression profiling we identified a downregulation of several angiogenic factors in isolated glomeruli of human kidneys with DN. 12 Here, we extend these results by studying the gene expression levels of VEGF-A and CTGF in renal biopsies from patients with DN. Using a combination of immunohistochemistry and quantitative PCR, we quantified the number of podocytes and endothelial cells and related this to the gene expression levels of VEGF-A and CTGF. Correlations of expression levels with clinical parameters and morphological changes were tested to obtain further insight into the role of these molecules in the development of DN.
RESULTS

Microarray experiments
In earlier gene expression profiling experiments on isolated glomeruli from patients with DN, we found a significant decrease in mRNA levels for VEGF-A and CTGF (19.5 and 6.5 times, respectively). 12 To further expand the scope of these investigations, we have performed oligonucleotide microarray profiling of RNA isolated from the total cortical part of kidneys from the same patients as those described in the previous study. A total of six chips were hybridized with RNA from three controls and three patients with DN. Results of these experiments can be found in qdetail at http://www-onderzoek.lumc.nl/pathology/kidney/ diabeticnephropathy/. Whole renal cortex mRNA levels of VEGF-A (2.2 times) and CTGF (1.7 times) were decreased, whereas expression of fibronectin (1.7 times) was increased in patients with DN compared with controls.
Clinical parameters
Having identified transcripts as being differentially regulated in DN using oligonucleotide microarrays, we validated their mRNA levels in a large, independent group of 28 patients and 22 controls. Protein excretion and serum creatinine levels at the time of biopsy for the patients with DN are depicted in Figure 1 . Serum creatinine levels ranged from 70 to 700 mmol/l (Figure 1a ) and protein excretion ranged from 0.061 to 6.7 g/l (Figure 1b) . There was no difference in age (60.0710.9 years versus 61.6710.0 years) between diabetic patients and controls.
Glomerular and whole cortical mRNA levels VEGF-A mRNA levels in microdissected glomeruli as measured by quantitative PCR were decreased 2.6. times (Po0.01) in patients with DN compared with control kidneys (Figure 2a ). In whole renal cortex RNA, VEGF-A mRNA levels in patients with DN were decreased 2.5 times compared with controls (Po0.01) (Figure 2c) . A similar pattern of downregulation was observed for CTGF: glomerular and whole renal cortex mRNA levels for CTGF were 1.6 times decreased (Po0.05) in patients with DN (Figure 2b and d). As expected, fibronectin mRNA levels were 2.8 and 1.9 times increased in glomerular and interstitial samples from diabetic patients compared with controls (Po0.05 for both comparisons).
The glomerular mRNA expression levels for the podocytespecific genes are shown in Figure 3 . Nephrin, podocin, and Wilms tumor1(WT1) were 2.8, 3.3, and 1.7 times decreased in DN compared with controls (Po0.05, Figure 3a -c).
(Immuno)histochemistry Interstitial fibrosis was quantified by morphometric analysis on frozen sections stained with Sirius Red (Figure 4 ). There was a significant increase in the extent of Sirius Red staining in patients with DN compared with controls (33.3 versus 18.7%, Po0.01) (Figure 5a ). CD31 (platelet-endothelial cell adhesion molecule) staining was used as a marker for endothelial cells. Both in the glomerular (Figure 5b ) and tubulo-interstitial compartment (Figure 5c ), the CD31-positive area in patients with DN was significantly decreased compared with controls (7.0 versus 22.6% in glomeruli and 5.8 versus 9.9% in the tubulo-interstitium), suggesting a reduction in the number of capillaries/endothelial cells in DN. Representative pictures of these stainings are depicted in Figure 4 . To confirm the reduction of VEGF-A, CTGF, and WT1 mRNA expression, we performed immunohistochemical stainings for these proteins. VEGF-A staining of the podocytes in the glomerulus was reduced in patients with DN (Figure 6a and b) . In control patients, CTGF showed staining in the mesangium and among the glomerular capillary wall. In diabetic patients, this staining largely disappeared. Occasionally, positive cells were present in the mesangium and in Bowman's capsule (Figure 6c and d) . Quantification of 
Correlations
To identify statistically significant relationships between variables, Pearson correlations were calculated between clinical, (immuno)histochemical, and mRNA data. Results of these correlations within the diabetic patient group are summarized in Table 1 . There was a positive correlation between glomerular VEGF-A and CTGF mRNA levels (R ¼ 0.61, Po0.01). When evaluating all samples together (controls and DN), a significant correlation was found between glomerular VEGF-A and the CD31-positive area, both for the glomerular (R ¼ 0.50, Po0.01) and the tubulo-interstitial compartments (R ¼ 0.42, Po0.01). We also found a correlation between the Sirius Red-positive area and serum creatinine levels (R ¼ 0.411, Po0.01) and proteinuria (R ¼ 0.593, Po0.01), and between the glomerular CD31-positive area and the mean of podocyte-specific mRNA levels (R ¼ 0.425, Po0.01). There was a negative correlation between Sirius Red staining and both glomerular and interstitial CD31 staining (R ¼ À0.654, Po0.01 and R ¼ À0.451, Po0.01, respectively).
DISCUSSION
In this study, we analyzed the angiogenic factors, VEGF-A and CTGF, in renal biopsies from patients with DN and healthy controls. We found a downregulation for glomerular VEGF-A and CTGF mRNA levels. This downregulation was correlated with reduction of podocytes and the progression of renal disease. The genes measured in this study were identified using microarray analysis of glomerular and tubulo-interstitial mRNA from diabetes patients with DN and healthy controls. Differentially expressed transcripts included several genes that play a role in endothelial cell maintenance and angiogenesis. To explore the implications of these gene expression alterations, a number of these genes were further investigated in a larger group of patients with different stages of DN.
VEGF-A is one of the most important angiogenic growth factors regulating vasculogenesis and permeability of endothelial cells. 19 Our results show decreased VEGF-A mRNA levels in patients with DN. Bailey et al. 20 found a decrease in VEGF-A mRNA in glomeruli from patients with DN using in situ hybridization. These results were confirmed by others in both the interstitial 21 and the glomerular compartments. 13 In addition, a negative correlation was found between glomerular VEGF-A levels and proteinuria. 21 Results from animal studies on the action of VEGF-A are contradictory. In STZinduced diabetic rats, treatment with anti-VEGF-A antibodies decreased hyperfiltration, albuminuria, and glomerular hypertrophy. 22 Tumstatin peptide, an inhibitor of angiogenesis, suppressed glomerular matrix expansion, the development of albuminuria, and renal mRNA expression of VEGF-A in STZ-induced diabetic mice. 23 In contrast, another study report that glomerular expression of VEGF-A is reduced 1 week after STZ induction. 10 This reduction could be restored by treatment of the rats with insulin. 10 Decreased VEGF-A expression was recently documented in the remnant kidney model, and treatment of these animals with VEGF-A reduces renal fibrosis. 24 Studies in mice show that glomerular-selective depletion or overexpression of VEGF-A leads to glomerular abnormalities. 25, 26 It is known from other studies that CTGF plays a role in angiogenesis, 14, 15 suggesting that, similar to VEGF-A, CTGF in the podocyte may be involved in endothelial maintenance. In our study, CTGF mRNA expression levels were downregulated in both the glomerular and tubulo-interstitial compartments of the diabetic kidney. These results are contradictory to those from a number of other studies that found increased CTGF levels in DN. [27] [28] [29] [30] However, some of these data represented the number of mRNA molecules per glomerulus whereas our data represent relative steady-state mRNA levels corrected for three different housekeeping genes. Another reason for the differences between our findings and those reported in the literature may be that the stage of the disease studied is different. Animal models are often studied in an early phase of the disease, whereas most of our patients were already in a moderate to severe stage of the disease. In patient studies, it is difficult to receive Sometimes, a positive cell could be found in the mesangium (arrowhead) and in Bowman's capsule (e, and f show a representative picture of WT1 staining of (e) a control and (f) a DN sample.
biopsy material at an early stage of disease, as patients do not normally present to a nephrologist until the disease has become manifest. It is also likely that mechanisms for initiation and progression of DN in animals differ from those seen in humans. 31 Because of the fact that all genes measured in our study were downregulated, we measured fibronectin mRNA. Fibronectin is one of the major extracellular matrix proteins present in glomerulosclerotic and interstitial fibrotic lesions, which was upregulated from our microarray experiments. As expected, fibronectin mRNA levels showed an increase in patients with DN compared with controls, indicating an ongoing process of glomerular and interstitial fibrogenesis.
As histological grading of tubulo-interstitial fibrosis is closely correlated with the loss of renal function, 32 quantitative measurements of the Sirius Red staining were used as a morphological marker for disease progression. We found a significant increase in the extent of Sirius Red staining in patients with DN compared with controls. The observation that glomerular VEGF-A mRNA levels negatively correlated with the extent of Sirius Red staining supports the concept that loss of VEGF-A is related to progression of DN. This was already suggested by Bortoloso et al. 13 who found a negative correlation between VEGF-A levels and urinary protein excretion.
The question remains by what mechanism VEGF-A and CTGF are downregulated in DN. One explanation may be that specific downregulation occurs in a diabetic milieu. This is unlikely as cell culture experiments have shown that glucose, insulin, and advanced glycated end products increase levels of VEGF-A and CTGF. [33] [34] [35] [36] It is more likely that the decrease in expression of angiogenic factors, normally produced by podocytes, results from podocyte loss. It has been shown that the number of podocytes decreases over the course of DN. 16, 17 Podocyte loss can be the result of high glucose levels, 37 raised insulin levels, 38 or hypertension. 39 In this study, we found a decrease in the mRNA expression of the podocyte-specific genes nephrin, podocin, and WT1. The expression of these genes showed a strong correlation with the number of podocytes as measured by WT1 staining. This suggests that the synchronous decrease in expression of these molecules can be used as a marker of podocyte loss. There was a high correlation of VEGF and CTGF expression levels with the expression of podocyte-specific genes and the number of podocytes. Taken together, this suggests that the observed decreases in angiogenic factors result from the loss of podocytes. From the results of this study, we speculate that loss of angiogenic factors contributes to the progression of DN. Podocyte loss leads to a reduction in expression of angiogenic factors, which are necessary for the normal maintenance of the endothelial cells. Indeed, injured podocytes are ineffective in mediating glomerular endothelial angiogenesis, proliferation, and migration, as a result of decreased VEGF-A and Ang-1. 40 The reduced endothelial cell maintenance in combination with endothelial cell dysfunction leads to a loss of endothelial cells. This endothelial cell loss may lead to thrombotic microangiopathy followed by loss of capillaries. Development of the latter has been shown by fragmented red blood cells and PAI-1, a marker for progression of thrombosis to sclerosis, in glomeruli from diabetic patients with severe nodular lesions. 41 Taken together, these findings are consistent with a model in which the endothelial cell defects result from direct endothelial damage as a result of diabetic factors and rom podocyte loss leading to diminished production of pro-angiogenic factors.
In conclusion, this study demonstrates a reduction in mRNA levels of angiogenic factors in glomerular and whole kidney mRNA samples from renal biopsies of patients suffering from type II diabetes-induced DN. Reduction of angiogenic factors correlated with the extent of interstitial fibrosis and a reduction of podocytes. We also found a reduction of glomerular and interstitial endothelial cells in DN. The results may suggest an important role for angiogenic factors in the maintenance of endothelial cells. Reduced expression of angiogenic factors may be involved in the progression of DN.
MATERIALS AND METHODS Array studies on diabetic kidneys
We extended our previously reported gene expression profiling on isolated glomeruli from diabetic kidneys 12 by profiling whole cortical RNA. Kidneys from deceased donors were obtained from Eurotransplant. These kidneys were unsuitable for transplantation owing to technical or morphological reasons. 12 Three control kidneys and three kidneys from patients with DN were used. Clinical information about these patients is listed in Table 2 . Hybridizations were performed on the Human Genome U95Av2 Array (Affymetrix, Santa Clara, CA, USA). Ten micrograms of total cortical RNA was converted to complementary DNA, double stranded DNA, and transcribed in vitro according to the instructions of the manufacturer. After hybridization, the microchips were scanned and analyzed with Affymetrix Microarray Suite 5.0 software. Statistics of this method are available at http://www.affymetrix.com/support/ technical/manuals.affx.
To identify which genes of expression was altered consistently in the disease samples, we used either those genes that were present on all six chips or those present in all three control samples but absent in all three diabetic samples, or vice versa. We employed multiple pair-wise comparisons between control and disease groups using the OpenStat statistics package (Student's t-test, Po0.01).
Renal biopsies
To confirm and extend the results of the array experiments, we selected frozen biopsies from patients with DN (n ¼ 28) from the pathology archive of the Leiden University Medical Center and the Institute for Clinical Pathology, Heidelberg. All patients had type II diabetes. DN was histologically confirmed in periodic acid-schiff stained paraffin sections. Criteria for DN included glomerular hypertrophy, diffuse mesangial and focal nodular glomerulosclerosis, arteriolar hyalinosis, focal and segmental glomerulosclerosis, the presence of hyaline drops between Bowman's capsule and epithelial cells, and interstitial fibrosis. Serum creatinine levels and albumi-nuria of the patients are depicted in Figure 1 . As a control group (n ¼ 22), we used native kidneys with normal function and histology obtained at autopsy (n ¼ 3), cadaver donor kidneys unsuitable for transplantation for technical reasons (n ¼ 7), and the non-affected part of tumor nephrectomy samples (n ¼ 12). Clinical information about diabetic patients and controls is available on our website (http:// www-onderzoek.lumc.nl/pathology/kidney/diabeticnephropathy/). There were no significant differences between the different control groups for any of the parameters measured. Patient studies were approved by the Institutional Ethical Committee.
Microdissection and RNA isolation from glomeruli
The PALM Laser-MicroBeam System (Wolfratshausen, Germany) was used for microdissection of glomeruli from renal biopsies according to the method of Specht et al. 42 In brief, three 4 mm cryosections were put on a polyethylene foil-coated slide. After selecting the glomeruli (2075 glomeruli from each biopsy), they were dissected with a laser beam and catapulted into a reaction tube containing RLT buffer (RNeasy kit, Qiagen GmbH, Germany). RNA was isolated from these glomeruli with Trizol, according to the manufacturer's instructions.
RNA isolation from renal cortex
Cryostat sections were cut from each biopsy. The presence of cortex was confirmed by light-microscopic localization of glomeruli in the sections. Ten 10 mm sections were cut and collected in a reaction tube. RNA was isolated using RNeasy Mini columns (Qiagen GmbH, Germany), according to the manufacturer's instructions.
cDNA synthesis RNA from microdissected glomeruli and whole cortex was converted to cDNA using avian myeloblastosis virus reverse transcriptase (Roche Applied Science, Almere, The Netherlands) in combination with oligo-dT and random hexamer priming. RNA without reverse transcriptase was used as negative control.
Quantitative real-time PCR Quantitative real-time PCR 43 was used in combination with Taqman probes to quantify the gene transcription levels for VEGF-A and CTGF. The primer/probe combination for VEGF detects all isoforms of VEGF-A. Glomerular gene transcription levels for podocin, nephrin, and WT1 were measured. The mean of these three podocyte-specific genes was used as a measure for the number of podocytes. Primer and probe sequences are listed in Table 3 . Details concerning the quantitative PCR protocol have been described elsewhere. 44 The transcription levels of the genes of interest were determined and corrected to a panel of three housekeeping genes, that is, glyceraldehyde-phosphate-dehydrogenase, hypoxanthine phosphoribosyl transferase, and TATA boxbinding protein, as described by Vandesompele et al. 45 These housekeeping genes were selected from a panel of five different housekeeping genes 46 on the basis of the highest correlations between each other (RX0.85). The relative values of each of the three different housekeeping genes of the controls were adjusted to one by dividing the samples by the mean of all samples. After this correction, the mean of the three different housekeeping genes was calculated. The relative expression levels of the genes of interest were obtained by dividing the value of the gene by the mean of the different housekeeping genes. The relative values of the controls were set to one.
(Immuno)histochemistry Sirius Red staining was used to quantify the amount of interstitial fibrosis 47 as a marker for progression of renal disease. 48, 49 IHC stainings were performed for VEGF-A, CTGF, endothelial cells (CD31), and podocytes (WT1). In brief, the slides were washed in phosphate-buffered saline and incubated for 2 h at room temperature with the primary antibody (rabbit anti-CD31 (Dako, Glostrup, Denmark) anti-WT1, anti-VEGF, and anti-CTGF (Abcam plc, Cambridge, UK). After washing with phosphate-buffered saline, the slides were incubated for 30 min with horseradish peroxidase conjugated anti-rabbit Envision (Dako, Glostrup, Denmark), and the staining was developed with diaminobenzidine. The color was enhanced by rinsing the slides in 0.5% CuSO 4 solution for 5 min. After counterstaining with hematoxylin, the slides were dehydrated and mounted. To avoid inter-assay variation, all sections were stained in one session.
Digital image analysis
Digital image analysis was performed using a Zeiss microscope equipped with a full-color 3CCD camera (Sony DXC 950p) and KS-400 image analysis software version 3.0. (Zeiss-Kontron, Eching, Germany). Images of all glomeruli (3-15) present in the slides were taken and the percentage of the area stained for CD31 was calculated and used as a measure for the number of endothelial cells. To quantify the number of podocytes, the number of WT1-positive nuclei per glomerulus was counted in 15 representative biopsies. In 10 adjacent microscopic fields of renal cortex, the percentage of Sirius Red-positive area was quantified as a measure of interstitial fibrosis.
Statistics
Statistical analysis for comparison of mRNA expression, Sirius Redstained area, and CD31-stained area between groups was performed using independent Student's t-test. Pearson correlations were calculated using SPSS 10.0.1 software. Po0.05 were considered significant. AAACCCTGAGGGAGGCTCC  TACTTGCAGATGTGACAAGCCG  CCTCCTGCCCGGCTCACCGC  CTGF  GGAAGAGAACATTAAGAAGGGCAA  CTCGGTATGTCTTCATGCTGGTG  CGTACTCCCAAAATCTCCAAGCCTATCA  Fibronectin  GGAGAATTCAAGTGTGACCCTCA  TGCCACTGTTCTCCTACGTGG  AGGCAACGTGTTACGATGATGGGAAGACAT  WT1  GCCAGCCCGCTATTCGCAATC  GCTTGAATGAGTGGTTGGGGAACTG  SYBR  s green  Podocin  GGCTGTGGAGGCTGAAGC  CTCAGAAGCAGCCTTTTCCG  SYBR  s green  Nephrin  AGGACCGAGTCAGGAACGAAT  CTGTGAAACCTCGGGAATAAGACA  TCAGAGCTCCACGGTCAGCACAACAG  GAPDH  TTCCAGGAGCGAGATCCCT  CACCCATGACGAACATGGG  CCCAGCCTTCTCCATGGTGGTGAA  HPRT  TGACACTGGCAAAACAATGCA  GGTCCTTTTCACCAGCAAGCT  CTTGACCATCTTTGGATTATACTGCCTGACCA  TBP  CACGAACCACGGCACTGATT  TTTTCTTGCTGCCAGTCTGGAC  TGTGCACAGGAGCCAAGAGTGAAGA CTGF, connective tissue growth factor; GAPDH, glyceraldehydes-phosphate-dehydrogenase; HPRT, hypoxanthine phosphoribosyl transferase; TBP, Tata box-binding protein; VEGF, vascular endothelial growth factor; WT1, Wilms tumor 1.
